34 results on '"Sapena, Rosa"'
Search Results
2. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
- Author
-
Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Diaz, Jose Miguel Torregrosa, De Renzis, Benoit, Götze, Katharina S., Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Borhane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Schipp, Dorothea, Metzeler, Klaus H., Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Platzbecker, Uwe, and Adès, Lionel
- Published
- 2022
- Full Text
- View/download PDF
3. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes
- Author
-
Neukirchen-Strapatsas, Judith, Tuechler, Heinz, Porta, Matteo Della, Fenaux, Pierre, Guerci, Agnès, Haas, Rainer, Rossi, Marianna, Sapena, Rosa, Sperr, Wolfgang R., Strupp, Corinna, Stamatoullas, Aspasia, Valent, Peter, Germing, Ulrich, and Bennett, John M.
- Published
- 2019
- Full Text
- View/download PDF
4. Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
- Author
-
Le Bris, Yannick, Bouzy, Simon, Ménard, Audrey, Turlure, Pascal, Chevallier, Patrice, Gourin, Marie-Pierre, Dumas, Pierre-Yves, Thepot, Sylvain, Berceanu, Anna, Park, Sophie, Hospital, Marie-Anne, Cluzeau, Thomas, Torregrosa Diaz, Jose-Miguel, Devron, Louis, Sapena, Rosa, Chermat, Fatiha, Dimicoli Salazar, Sophie, Béné, Marie C, Fenaux, Pierre, and Peterlin, Pierre
- Published
- 2022
- Full Text
- View/download PDF
5. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
- Author
-
Itzykson, Raphael, Santini, Valeria, Thepot, Sylvain, Ades, Lionel, Chaffaut, Cendrine, Giagounidis, Aristoteles, Morabito, Margot, Droin, Nathalie, Lübbert, Michael, Sapena, Rosa, Nimubona, Stanislas, Goasguen, Jean, Wattel, Eric, Zini, Gina, Torregrosa Diaz, Jose Miguel, Germing, Ulrich, Pelizzari, Anna Maria, Park, Sophie, Jaekel, Nadja, and Metzgeroth, Georgia
- Published
- 2023
- Full Text
- View/download PDF
6. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases
- Author
-
Braun, Thorsten, de Botton, Stéphane, Taksin, Anne-Laure, Park, Sophie, Beyne-Rauzy, Odile, Coiteux, Valérie, Sapena, Rosa, Lazareth, Anne, Leroux, Geneviève, Guenda, Khaled, Cassinat, Bruno, Fontenay, Michaela, Vey, Norbert, Guerci, Agnès, Dreyfus, François, Bordessoule, Dominique, Stamatoullas, Aspasia, Castaigne, Sylvie, Terré, Christine, Eclache, Virginie, Fenaux, Pierre, and Adès, Lionel
- Published
- 2011
- Full Text
- View/download PDF
7. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients
- Author
-
Park, Sophie, Kelaidi, Charikleia, Sapena, Rosa, Vassilieff, Dominique, Beyne-Rauzy, Odile, Coiteux, Valérie, Vey, Norbert, Ravoet, Christophe, Cheze, Stéphane, Rose, Christian, Legros, Laurence, Stamatoullas, Aspasia, Escoffre-Barbe, Martine, Guerci, Agnès, Chaury, Marie-Pierre, Fenaux, Pierre, and Dreyfus, François
- Published
- 2010
- Full Text
- View/download PDF
8. Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study
- Author
-
Cluzeau, Thomas, Sebert, Marie, Loschi, Michael, Ades, Lionel, Thepot, Sylvain, Carre, Martin, Duployez, Nicolas, Sapena, Rosa, Chermat, Fatiha, Preudhomme, Claude, Fenaux, Pierre, and Robin, Marie
- Published
- 2023
- Full Text
- View/download PDF
9. FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study
- Author
-
Peterlin, Pierre, Gaschet, Joëlle, Turlure, Pascal, Gourin, Marie-Pierre, Dumas, Pierre-Yves, Thepot, Sylvain, Berceanu, Ana, Park, Sophie, Hospital, Marie Anne, Cluzeau, Thomas, Torregrosa-Diaz, Jose-Miguel, Drevon, Louis, Sapena, Rosa, Chermat, Fatiha, Dimicoli-Salazar, Sophie, Jullien, Maxime, Fenaux, Pierre, and Chevallier, Patrice
- Published
- 2023
- Full Text
- View/download PDF
10. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis
- Author
-
Beyne-Rauzy, Odile, Sebert, Marie, Sapena, Rosa, Zerazhi, Hacène, Legros, Laurence, Guerci-Bresler, Agnès, Ame, Shanti Natarjan, Germing, Ulrich, Santini, Valeria, Salvi, Flavia, Gioia, Daniela, Lunghi, Monia, Dreyfus, François, Fenaux, Pierre, Sindromi, Fdn Italiana, Registry, Dusseldorf Mds, Gyan, Emmanuel, Andrieu, Valerie, Sanna, Alessandro, Caille, Agnès, Schemenau, Jennifer, Sudaka, Isabelle, Siguret, Virginie, Malet, Michele, Park, Sophie, Bordessoule, Dominique, Mairesse, Jacques, Gelsi-Boyer, Véronique, Cheze, Stephane, Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Médecine Interne Onco-hématologie, Centre Hospitalier Général, Service d'Hématologie Clinique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Department of Haematology, Oncology and Clinical Immunology, Centre for Haematology and Oncology, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Service d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle (UMR 1131), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d’Hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes (UMR_S 765), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Économie et Statistique (CREST), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE Paris)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne et Immunopathologie, CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], IUH- Institut Universitaire d'hématologie, Université Paris Diderot - Paris 7 ( UPD7 ), CHRU Tours, CHRU Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC 1415, Institut National de la Santé et de la Recherche Médicale-Université Francois Rabelais [Tours], Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes ( UMR_S 765 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Cochin [AP-HP], Contrôle de la Réponse Immune B et des Lymphoproliférations ( CRIBL ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche en Économie et Statistique ( CREST ), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] ( ENSAI ) -École polytechnique ( X ) -École Nationale de la Statistique et de l'Administration Économique ( ENSAE ParisTech ), Centre de Recherche en Cancérologie de Marseille ( CRCM ), Aix Marseille Université ( AMU ) -Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Francois Rabelais [Tours], Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE ParisTech )-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Pediatrics ,medicine.medical_specialty ,classifications ,diagnostic haematology ,MDS ,neutropenia ,thrombocytopenia ,Hematology ,business.industry ,Myelodysplastic syndromes ,Neutropenia ,medicine.disease ,World health ,3. Good health ,[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Dysplasia ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,030220 oncology & carcinogenesis ,Immunology ,medicine ,Young adult ,business ,ComputingMilieux_MISCELLANEOUS ,030215 immunology - Abstract
International audience; no abstract
- Published
- 2016
11. EVIDENCE FOR DIFFERENT INTERACTIONS BETWEEN β1- AND β2-ADRENOCEPTOR SUBTYPES WITH ADENYLYL CYCLASE IN THE RAT BRAIN: A CONCENTRATION–RESPONSE STUDY USING FORSKOLIN
- Author
-
MORIN, DIDIER, SAPENA, ROSA, TILLEMENT, JEAN-PAUL, and URIEN, SAIK
- Published
- 2000
- Full Text
- View/download PDF
12. S-15176 reduces the hepatic injury in rats subjected to experimental ischemia and reperfusion
- Author
-
Settaf, Abdellatif, Zahidy, Mouna, Elimadi, Aziz, Sapena, Rosa, Alsamad, Issam Abd, Tillement, Jean-Paul, and Morin, Didier
- Published
- 2000
- Full Text
- View/download PDF
13. Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study
- Author
-
Rabian, Florence, Lambert, Jérôme, Barbieri, Daniela, Gruson, Berengere, Thepot, Sylvain, Braun, Thorsten, Vey, Norbert, Delaunay, Jacques, Legros, Laurence, Lejeune, Julie, Walter-petrich, Anouk, Sapena, Rosa, Droin, Nathalie, Chermat, Fatiha, Porteu, Francoise, Lusina, Daniel, Ades, Lionel, Solary, Eric, Fenaux, Pierre, and Itzykson, Raphael
- Published
- 2020
- Full Text
- View/download PDF
14. A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia
- Author
-
Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Torregrosa Diaz, Jose Miguel, De Renzis, Benoit, Götze, Katharina S., Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Bohrane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Schipp, Dorothea, Metzeler, Klaus H., Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, Platzbecker, Uwe, and Ades, Lionel
- Published
- 2020
- Full Text
- View/download PDF
15. Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
- Author
-
Itzykson, Raphael, Santini, Valeria, Chaffaut, Cendrine, Lionel, Ades, Thepot, Sylvain, Giagounidis, Aristoteles, Morabito, Margot, Droin, Nathalie, Luebbert, Michael, Sapena, Rosa, Nimubona, Stanislas, Goasguen, Jean E., Wattel, Eric, Zini, Gina, Torregrosa Diaz, Jose Miguel, Germing, Ulrich, Pelizzari, Anna Maria, Park, Sophie, Jaekel, Nadja, Metzgeroth, Georgia, Onida, Francesco, Navarro, Robert, Patriarca, Andrea, Stamatoulas Bastard, Aspasia, Puttrich, Martin, Mossuto, Sandra, Solary, Eric, Gloaguen, Silke, Chevret, Sylvie, Chermat, Fatiha, Platzbecker, Uwe, and Fenaux, Pierre
- Published
- 2020
- Full Text
- View/download PDF
16. Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network
- Author
-
Platzbecker, Uwe, Kubasch, Anne Sophie, Giagounidis, Aristoteles, Metzgeroth, Georgia, Jonasova, Anna, Herbst, Regina, Torregrosa Diaz, Jose Miguel, De Renzis, Benoit, Götze, Katharina, Huetter-Kroenke, Marie-Luise, Gourin, Marie-Pierre, Slama, Borhane, Dimicoli-Salazar, Sophie, Cony-Makhoul, Pascale, Laribi, Kamel, Park, Sophie, Jersemann, Katja, Tiebel, Oliver, Sockel, Katja, Gloaguen, Silke, Mies, Anna, Chermat, Fatiha, Thiede, Christian, Sapena, Rosa, Schlenk, Richard F., Fenaux, Pierre, and Ades, Lionel
- Published
- 2019
- Full Text
- View/download PDF
17. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
- Author
-
Santini, Valeria, Schemenau, Jennifer, Levis, Alessandro, Balleari, Enrico, Sapena, Rosa, Adès, Lionel, Guerci, Agnès, Beyne-Rauzy, Odile, Gourin, Marie-Pierre, Cheze, Stephane, Stamatoullas, Aspasia, Sanna, Alessandro, Gioia, Daniela, Cametti, Gianni, Ferrero, Dario, Raffoux, Emmanuel, Rose, Christian, Poloni, Antonella, Prebet, Thomas, Legros, Laurence, Natarajan-Amé, Shanti, Fenaux, Pierre, Germing, Ulrich, Dreyfus, François, and Park, Sophie
- Published
- 2013
- Full Text
- View/download PDF
18. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
- Author
-
Park, Sophie, Hamel, Jean-François, Toma, Andrea, Kelaidi, Charikleia, Thépot, Sylvain, Campelo, Maria Diez, Santini, Valeria, Sekeres, Mikkael A., Balleari, Enrico, Kaivers, Jennifer, Sapena, Rosa, Götze, Katharina, Müller-Thomas, Catharina, Beyne-Rauzy, Odile, Stamatoullas, Aspasia, Kotsianidis, Ioannis, Komrokji, Rami, Steensma, David P., Fensterl, Jaime, and Roboz, Gail J.
- Published
- 2017
- Full Text
- View/download PDF
19. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.
- Author
-
Gyan, Emmanuel, Andrieu, Valérie, Sanna, Alessandro, Caille, Agnès, Schemenau, Jennifer, Sudaka, Isabelle, Siguret, Virginie, Malet, Michèle, Park, Sophie, Bordessoule, Dominique, Mairesse, Jacques, Gelsi ‐ Boyer, Véronique, Cheze, Stéphane, Beyne ‐ Rauzy, Odile, Sébert, Marie, Sapena, Rosa, Zerazhi, Hacene, Legros, Laurence, Guerci ‐ Bresler, Agnès, and Amé, Shanti Natarjan
- Subjects
MYELODYSPLASTIC syndromes ,DIAGNOSIS ,HEMATOLOGY ,NEUTROPENIA - Abstract
The article focuses on diagnosing myelodysplastic syndrome according to the World Health Organization (WHO), which included a refractory cytopenia with unilineage dysplasia (RCUD) category in 2008. Topics discussed include findings of the rare occurrence of WHO 2008 refractory neutropenia (RN) and refractory thrombocytopenia (RT) diagnoses, diagnosis of single cytopenia after 2008, and AML progression in IN and IT.
- Published
- 2016
- Full Text
- View/download PDF
20. Molecular Properties and Pharmacokinetic Behavior of Cetirizine, a Zwitterionic H 1 -Receptor Antagonist
- Author
-
Morin, Christophe, Zini, Roland, Tillement, Jean-Paul, Bertelli, Aldo, Bertelli, Alberto A.E, Cormier, C, Tillement, J.-P, Lagrue, Gilbert, Simon, Nicolas, Tillement, J.P, Cormier, Anne, Charbonnier, Peggy, Louet, Hervé Le, Jolliet, Pascale, Urien, Saïk, Thiault, Laetitia, Brée, Françoise, Sapena, Rosa, Morin, Didier, Lehri-Boufala, Sonia, Ouidja, Mohand-Ouidir, Barbier-Chassefière, Véronique, Hénault, Emilie, Raisman-Vozari, Rita, Garrigue-Antar, Laure, Papy-Garcia, Dulce, Arendt, Thomas, Zhang, Ganlin, Zhu, Xiaoxin, Bao Huynh, Minh, Ouidir Ouidja, Mohand, Sepulveda-Diaz, Julia Elisa, Li, Ping, Huynh, Minh Bao, Carpentier, Gilles, Garcia-Filipe, Stephanie, Talhas-Perret, Sofia, van Kuppevelt, Toin, Martelly, Isabelle, Albanese, Patricia, Yue, X-L, Lehri, S, Barbier-Chassefière, C, Petit, P., Huang, Q-F, Barritault, Denis, Caruelle, C, Petit, Emmanuel, Kerros, Marie-Emmanuelle, Ikeda, Yasunori, Brugère-Picoux, Jeanne, Deslys, Jean-Philippe, Adjou, Karim, Barbosa, Isabelle, Garcia, Stephanie, Duchesnay, Arlette, Oudghir, Mustapha, Jenniskens, Guido, Miao, Hua-Quan, Guimond, Scott, Cebrian, José, Caruelle, Jean-Pierre, Turnbull, Jeremy, Laurencé, Céline, Rivard, Michael, Martens, Thierry, Buisson, Didier, Bourcier, Sophie, Sablier, Michel, Oturan, Mehmet, Roumegous, A., Barbier-Chassefiere, V., Caredda, S., Courty, J., Pagliara, Alessandra, Testa, Bernard, Carrupt, Pierre-Alain, Urien, Saik, Rihoux, Jean-Pierre, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de Pharmacologie, Centre de Tabacologie, Hôpital Albert Chenevier, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire de Chimie et Biologie des Métaux (LCBM - UMR 5249), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Croissance cellulaire, réparation et régénération tissulaires (CRRET), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), OTR3 Sarl, OTR3, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Recherches en cancérologie, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Neuroanatomy University of Leipzig, Leipzig University, College of Information and Electrical Engineering [Beijing] (CIEE), China Agricultural University (CAU), Department of Biochemistry, University of Nijmegen, Laboratoire Astrophysique de Toulouse-Tarbes (LATT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Biologie des Plantes et Innovation - UR UPJV 3900 (BIOPI), Université de Picardie Jules Verne (UPJV)-Transfrontalière BioEcoAgro - UMR 1158 (BioEcoAgro), Université d'Artois (UA)-Université de Liège-Université de Picardie Jules Verne (UPJV)-Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Université d'Artois (UA)-Université de Liège-Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Laboratoire d'océanographie de Villefranche (LOV), Observatoire océanologique de Villefranche-sur-mer (OOVM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Groupe d'Innovation Diagnostique et Thérapeutique sur les Infections à Prions, Département de Recherche Médicale-DSV/DRM-Commissariat à l'Energie Atomique (CEA-Fontenay aux Roses), Institut de Biologie François JACOB (JACOB), Cancer and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, School of Biological Sciences, University of Liverpool, Institut de Chimie et des Matériaux Paris-Est (ICMPE), Institut de Chimie du CNRS (INC)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie Moléculaire Organique (ICMO), Université Paris-Sud - Paris 11 (UP11), Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physico-chimie des Polymères et des Interfaces (LPPI), Fédération INSTITUT DES MATÉRIAUX DE CERGY-PONTOISE (I-MAT), Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine-Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine, Laboratoire des mécanismes réactionnels (DCMR), École polytechnique (X)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université de Lausanne = University of Lausanne (UNIL), Laboratoire de chimie analytique pharmaceutique (LCAP), Université de Genève = University of Geneva (UNIGE)-Ecole de Pharmacie Genève Lausanne (EPGL), Unité de Soins Intensifs [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Université de Picardie Jules Verne (UPJV), Université de Lausanne (UNIL), University of Geneva [Switzerland]-Ecole de Pharmacie Genève Lausanne (EPGL), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Models, Molecular ,Octanols ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,Blood Proteins/metabolism ,Molecular Conformation ,[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC] ,01 natural sciences ,chemistry.chemical_compound ,Betaine ,Drug Discovery ,[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB] ,Cetirizine/*chemistry/metabolism/*pharmacokinetics ,ComputingMilieux_MISCELLANEOUS ,Histamine H1 Antagonists/*chemistry/metabolism/*pharmacokinetics ,ddc:615 ,0303 health sciences ,biology ,[SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Structural Biology [q-bio.BM] ,Brain ,Blood Proteins ,Hydrogen-Ion Concentration ,Cetirizine ,Dissociation constant ,Hydroxyzine ,Lipophilicity ,Histamine H1 Antagonists ,Molecular Medicine ,medicine.drug ,Stereochemistry ,Serum albumin ,Hydroxyzine/chemistry ,03 medical and health sciences ,Isomerism ,Pharmacokinetics ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Alkanes ,medicine ,Animals ,Brain/metabolism ,Humans ,[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,030304 developmental biology ,010401 analytical chemistry ,Antagonist ,Water ,Biological Transport ,Hydrogen Bonding ,Rats ,0104 chemical sciences ,chemistry ,Zwitterion ,biology.protein ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology - Abstract
The ionization and lipophilicity behavior of the antihistamine (H1-receptor antagonist) cetirizine was investigated, showing the drug to exist almost exclusively as a zwitterion in the pH region 3.5-7.5. In this pH range, its octanol/water lipophilicity is constant and low compared to cationic antihistamines (log D = log PZ = 1.5), whereas its H-bonding capacity is relatively large (delta log PZ > or = 3.1). Conformational, electronic, and lipophilicity potential calculations revealed that zwitterionic cetirizine experiences partial intramolecular charge neutralization in folded conformers of lower polarity. Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects. As such, cetirizine does not differ from "second-generation" antihistamines. In contrast, its very low apparent volume of distribution in humans (0.4 L kg-1, smaller than that of exchangeable water) implies a low affinity for lean tissues such as the myocardium and is compatible with the absence of cardiotoxicity of the drug. The zwitterionic nature and modest lipophilicity of cetirizine may account for this pharmacokinetic behavior. The suggestion is offered that cetirizine and analogous zwitterions, whose physicochemical, pharmacokinetic, and pharmacodynamic properties differ from those of "first-" and "second-generation" drugs in this class, could be considered as "third-generation" antihistamines.
- Published
- 1998
21. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore
- Author
-
Morin, Didier, Elimadi, Aziz, Sapena, Rosa, Crevat, Aimé, Carrupt, Pierre-Alain, Testa, Bernard, and Tillement, Jean-Paul
- Subjects
Intracellular Membranes/metabolism ,Male ,ddc:615 ,Binding Sites ,Vasodilator Agents ,Trimetazidine ,Trimetazidine/*metabolism ,Mitochondria, Liver ,Intracellular Membranes ,In Vitro Techniques ,Vasodilator Agents/*metabolism ,Tritium ,Permeability ,Rats ,Subcellular Fractions/metabolism ,Papers ,Animals ,Rats, Wistar ,Subcellular Fractions ,Mitochondria, Liver/*metabolism - Abstract
1. Trimetazidine is an anti-ischaemic drug effective in different experimental models but its mechanism of action is not fully understood. Data indicate that mitochondria could be the main target of this drug. The aim of this work was to investigate the binding of [3H]-trimetazidine on a purified preparation of rat liver mitochondria. 2. [3H]-trimetazidine binds to two populations of mitochondrial binding sites with Kd values of 0.96 and 84 microM. The total concentration of binding sites is 113 pmol mg(-1) protein. Trimetazidine binding sites are differently distributed. The high-affinity ones are located on the outer membranes and represent only a small part (4%) of total binding sites, whereas the low-affinity ones are located on the inner membranes and are more abundant (96%) with a Bmax=108 pmol mg(-1) protein. 3. Drug displacement studies with pharmacological markers for different mitochondrial targets showed that [3H]-trimetazidine binding sites are different from previously described mitochondrial sites. 4. The possible involvement of [3H]-trimetazidine binding sites in the regulation of the mitochondrial permeability transition pore (MTP), a voltage-dependent channel sensitive to cyclosporin A, was investigated with mitochondrial swelling experiments. Trimetazidine inhibited the mitochondrial swelling induced by Ca2+ plus tert-butylhydroperoxide (t-BH). This effect was concentration-dependent with an IC50 value of 200 microM. 5. Assuming that trimetazidine effectiveness may be related to its structure as an amphiphilic cation, we compared it with other compounds exhibiting the same chemical characteristic both for their ability to inhibit MTP opening and to displace [3H]-trimetazidine bound to mitochondria. Selected compounds were drugs known to interact with various biological membranes. 6. A strong correlation between swelling inhibition potency and low-affinity [3H]-trimetazidine binding sites was observed: r=0.907 (n=24; P
- Published
- 1998
22. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM
- Author
-
Drevon, Louis, Marceau, Alice, Eclache, Virginie, Raynaud, S. Dominique, Richez, Valentine, Berkaoui, Inès, Maarek, Odile, Cuccuini, Wendy, Lusina, Daniel, Berthon, Celine, Dimicoli-Salazar, Sophie, Bidet, Audrey, Vial, Jean-Philippe, Park, Sophie, Stamatoullas, Aspasia, Vieira Dos Santos, Christina, Braun, Thorsten, Sapena, Rosa, Renneville, Aline, Ades, Lionel, and Fenaux, Pierre
- Published
- 2015
- Full Text
- View/download PDF
23. Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study
- Author
-
Park, Sophie, Hamel, Jean-François, Toma, Andrea, Kelaidi, Charikleia, Campelo Diez, Maria, Santini, Valeria, Balleari, Enrico, Schemenau, Jennifer, Sapena, Rosa, Goetze, Katharina, Mueller-Thomas, Catharina, Beyne-Rauzy, Odile, Stamatoullas, Aspasia, Kotsianidis, Ioannis, Guerci, Agnes, Bordessoule, Dominique, Cony-Makhoul, Pascale, Cheze, Stéphane, Wattel, Eric, Rose, Christian, Vey, Norbert, Germing, Ulrich, Sanz, Guillermo, Dreyfus, François, and Fenaux, Pierre
- Published
- 2015
- Full Text
- View/download PDF
24. The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism
- Author
-
Santini, Valeria, Schemenau, Jennifer, Levis, Alessandro, Balleari, Enrico, Sapena, Rosa, Ades, Lionel, Guerci, Agnès, Beyne-Rauzy, Odile, Gourin, Marie Pierre, Cheze, Stéphane, Stamatoullas, Aspasia, Sanna, Alessandro, Gioia, Daniela, Cametti, Giani, Ferrero, Dario, Raffoux, Emmanuel, Rose, Christian, Antonella, Poloni, Prebet, Thomas, Ame, Shanti, Legros, Laurence, Fenaux, Pierre, Germing, Ulrich, Dreyfus, Francois, and Park, Sophie
- Published
- 2013
- Full Text
- View/download PDF
25. Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes.
- Author
-
Klouz, Anis, Sapena, Rosa, Jun Liu, Maurice, Tangui, Tillement, Mean-Paul, Papadopoulos, Vassilios, and Morin, Didier
- Subjects
- *
PENTAZOCINE , *BINDING sites , *OPIOID receptors , *MITOCHONDRIAL membranes , *LABORATORY rats - Abstract
1 Sigma (σ) receptors have generated a great deal of interest on the basis of their possible roles in various pathologies, including cytoprotection Although the exact function of sigma-1 (σ[sub1]) receptors is not yet known, their role in the regulation of intracellular Ca[sup2+]. levels and sterol biosynthesis, functions that could be assigned to mitochondria, are the only mechanisms described. 2 Using preparations of purified rat liver and brain mitochondria we demonstrate herein the presence of σ-like binding sites [[sup3]H]( + )-pentazocine, a σ[sub1] radioligand was used to label these sites. 3 In the liver, [[sup3]H] (+ )-pentazocine labelled one class of binding sites with high affinity (K[subd] = 3 nM), similar to that observed in liver microsomes and synaptic membranes. These sites were located on the outer mitochondrial membranes and displayed high affinity for other σ[sub1] ligands namely, haloperidol. ifenprodil. carbetapentane or l,3-dt(2-tolyl)guanidine (DTG). 4 The presence of σ[sub1] receptors on liver mitochondria was confirmed using double fluorescence immunostaining. 5 [[sub3]H] (+ )-pentazocine binding sites were also found on brain mitochondria hut they appeared pharmacologically distinct to the liver ones as [[sub3]H] ( + )-pentazocine and typical σ[sub1] ligands displayed lower affinities for these sites. Nevertheless. [[sub3]H ]( + )-pentazocine binding on both liver and brain mitochondria was modulated by progesterone, a putative endogenous ligand for σ receptors. 6 Our data demonstrates the presence of [[sub3]H] ( + )-pentazocine binding sites with pharmacological characteristics identical to σ receptors on rat liver mitochondrial membranes. The pharmacological significance of these sites and their role on mitochondrial function remain unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
26. [3H]-Trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance.
- Author
-
Morin, Didier, Sapena, Rosa, Elimadi, Aziz, Testa, Bernard, Labidalle, Serge, Le Ridant, Alain, and Tillement, Jean-Paul
- Published
- 2000
- Full Text
- View/download PDF
27. Labelling of Rat Brain ß-Adrenoceptors: (3H)CGP-12177 or (125I)Iodocyanopindolol??
- Author
-
Morin, Didier, Zini, Roland, Urien, Saïk, Sapena, Rosa, and Tillement, Jean-Paul
- Published
- 1992
- Full Text
- View/download PDF
28. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore.
- Author
-
Morin, Didier, Elimadi, Aziz, Sapena, Rosa, Crevat, Aimé, Carrupt, Pierre-Alain, Testa, Bernard, and Tillement, Jean-Paul
- Published
- 1998
- Full Text
- View/download PDF
29. A MATCH BETWEEN BINDING TOβ-ADRENOCEPTORS AND STIMULATION OF ADENYLYL CYCLASE PARAMETERS OF (−)ISOPROTERENOL AND SALBUTAMOL ON RAT BRAIN
- Author
-
GARNIER, VINCENT, ZINI, ROLAND, SAPENA, ROSA, and TILLEMENT, JEAN-PAUL
- Published
- 1997
- Full Text
- View/download PDF
30. Serotonin enhances the β-adrenergic response in rat brain cortical slices
- Author
-
Morin, Didier, Sapena, Rosa, Zini, Roland, and Tillement, Jean-Paul
- Published
- 1992
- Full Text
- View/download PDF
31. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
- Author
-
Jennifer Kaivers, Ulrich Germing, Rosa Sapena, Giovanni Cametti, Mikkael A. Sekeres, Katharina Götze, Maria Diez Campelo, Agnès Guerci-Bresler, Fabrizio Pane, Stéphane Cheze, François Dreyfus, Teresa Bernal, Enrico Balleari, David P. Steensma, Rami S. Komrokji, Pierre Fenaux, Christian Rose, Guillermo Sanz, Valeria Santini, Catharina Müller-Thomas, Marisa Calabuig, Aspasia Stamatoullas, Norbert Vey, Dario Ferrero, Alessandro Sanna, Jean Francois Hamel, Jaime Fensterl, Dominique Bordessoule, Ioannis Kotsianidis, Sophie Park, Andrea Toma, Charikleia Kelaidi, Gail J. Roboz, Fernando Ramos, Gianluca Gaidano, Sylvain Thepot, Odile Beyne-Rauzy, Pascale Cony-Makhoul, Eric Wattel, Daniela Gioia, Park, Sophie, Hamel, Jean Françoi, Toma, Andrea, Kelaidi, Charikleia, Thépot, Sylvain, Campelo, Maria Diez, Santini, Valeria, Sekeres, Mikkael A, Balleari, Enrico, Kaivers, Jennifer, Sapena, Rosa, Götze, Katharina, Müller Thomas, Catharina, Beyne Rauzy, Odile, Stamatoullas, Aspasia, Kotsianidis, Ioanni, Komrokji, Rami, Steensma, David P, Fensterl, Jaime, Roboz, Gail J, Bernal, Teresa, Ramos, Fernando, Calabuig, Marisa, Guerci Bresler, Agnè, Bordessoule, Dominique, Cony Makhoul, Pascale, Cheze, Stéphane, Wattel, Eric, Rose, Christian, Vey, Norbert, Gioia, Daniela, Ferrero, Dario, Gaidano, Gianluca, Cametti, Giovanni, Pane, Fabrizio, Sanna, Alessandro, Germing, Ulrich, Sanz, Guillermo F, Dreyfus, Françoi, and Fenaux, Pierre
- Subjects
Male ,Cancer Research ,0302 clinical medicine ,Recurrence ,Risk Factors ,hemic and lymphatic diseases ,Hydroxyurea ,Cumulative incidence ,Treatment Failure ,Enzyme Inhibitors ,Lenalidomide ,Aged, 80 and over ,Cytarabine ,Anemia ,Middle Aged ,Thalidomide ,Melodysplastic syndrome ,Survival Rate ,Leukemia, Myeloid, Acute ,Oncology ,International Prognostic Scoring System ,030220 oncology & carcinogenesis ,Retreatment ,Azacitidine ,Cyclosporine ,Disease Progression ,Chromosomes, Human, Pair 5 ,Female ,Chromosome Deletion ,Erythrocyte Transfusion ,medicine.drug ,medicine.medical_specialty ,Melodysplastic syndrome, erytropoiesis stimulating agents, 5q ,erytropoiesis stimulating agents ,Decitabine ,Antineoplastic Agents ,Tretinoin ,Lower risk ,5q ,Arsenic ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Survival rate ,Aged ,Antilymphocyte Serum ,Retrospective Studies ,business.industry ,Valproic Acid ,Myelodysplastic syndromes ,Retrospective cohort study ,medicine.disease ,Myelodysplastic Syndromes ,Hematinics ,Physical therapy ,business ,030215 immunology - Abstract
Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 61.5%, and median response duration was 17 months. Of 1,147 patients experiencing ESA failure, 653 experienced primary failure and 494 experienced relapse after a response. Primary failure of ESAs was associated with a higher risk of acute myeloid leukemia (AML) progression, which did not translate into an OS difference. Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received LEN, and 108 received other treatments (MISC), whereas 697 received RBC transfusions only. Five-year AML cumulative incidence was 20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and MISC, respectively ( P = .05). Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%, and 51%, respectively ( P = .21). In a multivariable analysis adjusted for age, sex, revised International Prognostic Scoring System score, and progression at ESA failure, there was no significant OS difference among the three groups. Conclusion In this large, multicenter, retrospective cohort of patients with non-del(5q) lower-risk MDS treated with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly improved OS. Early failure of ESAs was associated with a higher risk of AML progression.
- Published
- 2017
32. Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study.
- Author
-
Rabian F, Chevret S, Gruson B, Thépot S, Walter-Petrich A, Braun T, Vey N, Torregrosa-Diaz JM, Peterlin P, Toma A, D'Aveni M, Delaunay J, Legros L, Droin N, Chermat F, Lusina D, Adès L, Sapena R, Solary E, Fenaux P, and Itzykson R
- Published
- 2024
- Full Text
- View/download PDF
33. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
- Author
-
Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, and Fenaux P
- Subjects
- Aged, Female, Humans, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Male, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes mortality, Risk, Survival Analysis, Treatment Outcome, Azacitidine analogs & derivatives, Azacitidine therapeutic use, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes drug therapy
- Abstract
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine in high-risk myelodysplastic syndrome and low blast count acute myeloid leukemia patients refractory or relapsing after azacitidine. We included 56 patients with a median age of 75 years [Interquartile Range (IQR) 69-76]. Fifty-five patients received at least one cycle of guadecitabine (60 mg/m2/d subcutaneously days 1-5 per 28-day treatment cycles), with a median of 3 cycles (range, 0-27). Eight (14.3%) patients responded, including two complete responses; median response duration was 11.5 months. Having no or few identified somatic mutations was the only factor predicting response ( P =0.035). None of the 11 patients with TP53 mutation responded. Median overall survival was 7.1 months, and 17.9 months in responders (3 of whom had overall survival >2 years). In multivariate analysis, IPSS-R (revised International Prognostic Scoring System) score other than very high ( P =0.03) primary versus secondary azacitidine failure ( P =0.01) and a high rate of demethylation in blood during the first cycle of treatment ( P =0.03) were associated with longer survival. Thus, guadecitabine can be effective, sometimes yielding relatively prolonged survival, in a small proportion of high-risk myelodysplastic syndrome/low blast count acute myeloid leukemia patients who failed azacitidine. (Trial registered a t clinicaltrials.gov identifier: 02197676 )., (Copyright© 2019 Ferrata Storti Foundation.)
- Published
- 2019
- Full Text
- View/download PDF
34. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.
- Author
-
Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, and Fenaux P
- Subjects
- Adult, Aged, Antigens, Nuclear genetics, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic therapeutic use, Cell Cycle Proteins, Chromosomes, Human, Pair 8 genetics, Disease Progression, Enhancer of Zeste Homolog 2 Protein genetics, Female, Humans, Middle Aged, Myelodysplastic Syndromes epidemiology, Myeloproliferative Disorders drug therapy, Myeloproliferative Disorders mortality, Repressor Proteins genetics, Retrospective Studies, Survival Analysis, Myelodysplastic Syndromes genetics, Myeloproliferative Disorders genetics, Trisomy genetics
- Abstract
Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 × 10
9 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fifty-four patients (39·1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33·3% vs. 12·0% in non-MP, P = 0·047), ASXL1 (66·7% vs. 42·3%, P = 0·048) and STAG2 mutations (77·8% vs. 21·7%, P = 0·006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0·15) and 39 months (P = 0·085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms., (© 2018 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.